| With 2025 serving as a pivotal year for clinical data, VNRX recently presented two abstracts at the North America Conference on Lung Cancer, further validating the utility of Nu.Q® in hard-to-detect respiratory malignancies.
This continuous stream of clinical evidence is vital for securing regulatory approvals and insurance reimbursement.
Financial and Operational Strength
As of the third quarter 2025, VNRX reported a cash position of approx. $12.3Mn.
The company has been disciplined in its capital allocation, focusing on high-value commercial partnerships and streamlining its manufacturing processes.
The management team, led by CEO Cameron Reynolds, brings decades of experience in the biotechnology sector, specifically in bringing novel diagnostic tools to global markets.
Grab Sources And More Here: VNRX Website. VNRX Presentation. -----
5 Potential Catalysts Put (NYSE American: VNRX) Atop Our Watchlist This Week
#1. An Analyst $2.50 Target May Be Signaling Triple-Digit Potential Upside.
Last month, Zacks Small-Cap Research analyst, Steven Ralston, provided coverage on (NYSE American: VNRX) with a price forecast of $2.50.
From Wednesday's close, the target suggests a potential upside over 750%.
Here's some highlights from the report:
Outlook:
Management’s primary operational goal for 2025 is (was) to secure multiple licensing agreements for human diagnostic applications. In September Volition entered into two such licensing agreements.
The company’s 1st commercial order for Nu.Q Cancer assays was received in November.
The key financial goal for 2025 is (was) to achieve cash neutrality on a full-year basis. In 3Q 2025, cash burn was reduced to 1.2Mn per month.
Papers, posters, conference presentations, webinars etc. continue on a brisk pace.
#2. VolitionRx Revolutionizes Cancer Detection Through Groundbreaking DNA Enrichment Technology.
VolitionRx Limited unveiled a major advancement in liquid biopsy with its Capture-Seq™ method, achieving an unprecedented 180-fold (18,000%) enrichment of transcription factor-bound ultrashort DNA fragments.
This innovation isolates cancer-related DNA from background blood DNA, enabling highly accurate, low-cost cancer detection.
In initial trials, the method showed 100% sensitivity and specificity, even for early-stage cancers.
The breakthrough could transform cancer diagnostics, expand Volition’s Nu.Q® portfolio, and tap into an estimated $23Bn annual market, positioning Volition as a leader in next-generation cancer testing.
#3. VolitionRx Strengthens Global Impact With Inclusion In French Sepsis Program.
VolitionRx Limited’s Nu.Q® NETs H3.1 assay was selected as the exclusive biomarker in the French Government's €6.3Mn DETECSEPS program, funded under the France 2030 plan.
This real-world study aims to revolutionize early sepsis detection by combining Volition’s biomarker with the NEWS2 clinical score, improving diagnostic accuracy and patient outcomes.
Supported by major French hospitals and the government, this milestone highlights Volition’s growing global influence in clinical diagnostics and underscores the broad potential of its epigenetic technologies in saving lives and reducing healthcare burdens worldwide.
#4. VolitionRx Reaches Major Milestone With First Clinical Sale Of Nu.Q® Cancer Assays.
VolitionRx Limited achieved a major milestone with the first sale of its Nu.Q® Cancer assays to Hospices Civils de Lyon in France for clinical certification.
This step marks progress toward routine hospital use in cancer management.
Research led by Professor Léa Payen confirmed that Nu.Q® biomarkers provide powerful insights into survival and treatment strategies for lung cancer.
Volition’s technology enhances diagnostic precision, supports personalized care, and positions the company for commercial expansion in human oncology—advancing its mission to improve outcomes and save lives globally.
#5. VolitionRx Strengthens Growth With Strategic Partnerships And Solid Financial Progress.
VolitionRx Limited reported strong third-quarter 2025 results, highlighted by new human diagnostics partnerships and improved financial performance
Revenue rose 32% year over year, while operating expenses fell 10% and net loss decreased 8%, reflecting disciplined cost control.
Key achievements included agreements with global leaders Werfen and Hologic, expanding Volition’s Nu.Q® applications into autoimmune and diagnostic markets.
With growing clinical evidence, multiple negotiations underway, and groundbreaking Capture-Seq™ progress, Volition is well-positioned for sustained growth, new licensing deals, and global impact in cancer and sepsis detection. -----
We will be keeping a close watch on (NYSE American: VNRX) as it continues to roll out its Nu.Q® technology to laboratories and hospitals worldwide.
Be on watch for updates coming soon. Talk shortly.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 01/07/2026 and ending on 01/08/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (VNRX:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/vnrx-twph9/#details | 
